Psychopharmacology and Neurocognitive Disorders: Evidence for Cognitive and Behavioral Symptom Management
Focus · 2026-04 · 24 (2) · 179-187
DOI: 10.1176/appi.focus.20250042 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Focus, 2026-04. Verfasst von Cody Olson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Texas Southwestern, Dallas. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Neurocognitive disorders (NCDs) encompass various conditions that affect cognition and functioning in activities of daily living. Although many types of NCDs lack curative therapy, medications may be used to ameliorate cognitive as well as behavioral and psychological symptoms of dementia (BPSD). Medications classified as acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, and antiamyloid monoclonal antibodies target cognitive symptoms. For BPSD, antidepressants, antipsychotics, mood stabilizers, anxiolytics, and stimulants have been studied. Selection of pharmacotherapies requires careful risk-benefit analysis for individual patients. This review discusses available evidence to guide these discussions and clinical decisions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, University of Texas Southwestern, Dallas.
Zitieren
APA
Olson, C., Girón Bravo, M. M., Gonzalez, G., & Camp, M. E. (2026). Psychopharmacology and Neurocognitive Disorders: Evidence for Cognitive and Behavioral Symptom Management. Focus, 24(2), 179-187. https://doi.org/10.1176/appi.focus.20250042
Vancouver
Olson C, Girón Bravo MM, Gonzalez G, Camp ME. Psychopharmacology and Neurocognitive Disorders: Evidence for Cognitive and Behavioral Symptom Management. Focus. 2026;24(2):179-187. doi:10.1176/appi.focus.20250042
BibTeX
@article{Olson2026,
author = {Olson, Cody and Girón Bravo, Marlene Maria and Gonzalez, Gisela and Camp, Mary Elizabeth},
title = {Psychopharmacology and Neurocognitive Disorders: Evidence for Cognitive and Behavioral Symptom Management},
journal = {Focus},
year = {2026},
volume = {24},
number = {2},
pages = {179--187},
doi = {10.1176/appi.focus.20250042}
}
EUVIMED